Table 3

Model 1: The association of inflammatory sNfL level and fGd+ with MRI atrophy and clinical measures at the 10-year follow-up, corrected for age, sex, DMT use, eTIV, BL T2LC and Gd+ LC*


Mean inflammatory sNfL levelfGd+Full model
MRI/clinical measureNBStd. B95% CIP value†BStd. B95% CIP value†R2 adj.P value
Total GM volume25−850.8−0.399−1580.218 to –121.416 0.040 91 552.90.3623400.111 to 179 705.7710.0650.504<0.001
Total WM volume25NSNS
Total deep GM volume25−140.31−0.556−228.417 to −52.198 0.010 NS0.3410.004
Thalamus volume25NSNS
Mean Cth25−0.003−0.581−0.005 to −0.001 0.010 NS0.3080.002
logLesion volume‡28NSNS
logLesion count‡280.0040.4980.001 to 0.007 0.018 NS0.2200.007
EDSS≥4§31NSNS
logT25FW‡30NSNS
logChange in T25FW‡30NSNS
logD9-HPT‡290.0040.5930.002 to 0.006 0.004 NS0.4110.001
logChange in D9-HPT‡29NSNS
logND9-HPT‡29NSNS
logChange in ND9-HPT‡29−0.006−0.498−0.010 to −0.001 0.024 NS0.3990.002
PASAT28NSNS
Change in PASAT28NSNS
Oral SDMT28NSNS
  • *Non-significant covariates removed from final model by backward elimination.

  • †Adjusted p values after controlling the false discovery rate (FDR) for multiple hypothesis testing.

  • ‡Dependent variable log transformed due to non-normality (log-linear transformation).

  • §Analysed by logistic regression.

  • adj, adjusted; B, beta; BL, baseline; Cth, cortical thickness; D9-HPT, dominant hand Nine-Hole Peg Test; DMT, disease modifying therapy; EDSS, Expanded Disability Status Scale; eTIV, estimated total intracranial volume; fGd+, fraction of MRI scans with new Gadolinium-enhancing lesion; Gd+, gadolinium-enhancing; GM, grey matter; LC, lesion count; ND9-HPT, non-dominant hand Nine-Hole Peg Test; PASAT, Paced Auditory Serial Addition Test; SDMT, Symbol Digit Modalities Test; sNfL, serum neurofilament light chain; Std, standardised; T25FW, timed 25-foot walk; WM, white matter.